查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2100419

急性缺血性腦中風診斷市場－全球市場預測（2026-2032年）

Acute Ischemic Stroke Diagnosis Market - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，急性缺血性腦中風診斷市場將成長至 64.7 億美元，複合年成長率為 7.13%。

主要市場統計數據
基準年 2025 39.9億美元
預計年份：2026年 42.4億美元
預測年份 2032 64.7億美元
複合年成長率 (%) 7.13%

急性缺血性腦中風時間緊迫的臨床路徑，其重點在於快速識別動脈閉塞、排除出血、確定可挽救的腦組織，並指導再灌注治療決策，例如靜脈溶栓或血管內取栓術。由於缺血性中風佔全球卒中病例的絕大多數，診斷的速度和準確性直接影響患者的殘疾率、死亡率、住院時間和長期康復負擔。目前的工作流程擴大將人工智慧（AI）驅動的影像診斷技術與非造影CT、CT血管攝影檢查、CT灌注造影、磁振造影（MRI）、臨床實驗室檢查、中風嚴重程度評分和急診分流相結合。臨床需求顯而易見：大血管閉塞每耽誤一分鐘都可能導致嚴重的神經元喪失，因此，快速、標準化且可互操作的診斷系統對於急診室、綜合中風中心和基層卒中中心都至關重要。急性缺血性腦中風的診斷模式正受到人口老化、高血壓、糖尿病、心房顫動、肥胖和久坐生活方式盛行率上升，以及人們對評估短暫性腦缺血發作（TIA）和輕度中風必要性的認知不斷提高等因素的影響。醫療系統正優先考慮從入院到影像檢查、從入院到溶栓治療以及從鼠蹊部到腹股溝穿刺的快速診療流程，而卒中網路則在擴展遠距中風醫療、移動卒中單元、雲端影像傳輸和中心輻射式會診模式。對於產業相關人員而言，最大的商業機會在於加速實證診斷、提高主要血管閉塞和循環後卒中的檢出率、建立無縫銜接的工作流程，以及確保服務不足地區也能公平地獲得先進的神經影像技術。

急性缺血性腦中風診斷模式的變革性變化

急性缺血性腦中風的診斷格局正在經歷結構性變革，從依賴特定醫療機構的順序評估轉向基於規範流程、數位化協調的整合式診療。急診中風分診正逐步推進至院前階段，臨床醫生能夠透過院前中風評估量表、提前通知救護車以及移動影像程序，在患者到達醫院前識別潛在的大血管閉塞。院內診療路徑也在不斷發展，非造影CT仍然是排除顱內出血的重要第一線工具，而CT血管造影術和CT造影則擴大用於檢測血管閉塞、側支循環狀態、梗塞核心和缺血半暗帶。磁振造影（MRI），包括擴散加權成像，在某些患者中仍具有很高的敏感性，尤其是在發病時間不明或懷疑枕骨大窩中風的情況下。另一項突破性變革是擴大了特定患者的治療窗口，其依據不僅包括時間，還包括組織影像。實證中風診療方案現在強調個別化的取栓指徵影像學標準，從而推動了對快速灌注分析、標準化觀察解讀和多學科協作的需求。遠距中風醫療的引入透過促進當地醫院、血管神經科醫生和介入神經放射學團隊之間的協作，正在減少區域差異；而可互通的影像平台則有助於更快地做出轉診決策。同時，診斷品質受到監管預期、網路安全要求、資料管治以及放射科和神經科人員短缺的影響。因此，臨床應用所處的市場環境不僅取決於診斷準確性，還取決於工作流程相容性、實際可靠性、培訓要求、報銷相容性以及對治療時間線的可衡量影響。

人工智慧對中風診斷的累積影響

人工智慧正透過加速影像閱片、整體檢測主要血管閉塞、估算梗塞核心大小、評估灌注不匹配、輔助急性缺血性腦中風以及優先處理放射科工作清單中的緊急病例，對急性缺血性中風的整體診斷產生累積性影響。人工智慧工具可在懷疑存在閉塞或灌注異常時向中風團隊發送警報，從而累積影像解讀的延遲。這對於神經放射科人員配備有限的醫院尤其重要。在實際臨床實踐中，將人工智慧整合到整個中風工作流程中，包括影像擷取、自動處理、行動通知、跨學科協作、治療指徵評估和轉診協調，才能最大程度地發揮其價值。然而，人工智慧的影響並非均勻一致。模型性能會因掃描儀類型、成像方案、患者人口統計特徵、卒中樣疾病、迴路後閉塞、小規模梗塞灶以及運動引起的影像品質劣化等因素而有所不同。因此，臨床管治至關重要。成功的卒中計畫並非將人工智慧定位為獨立的診斷工具，而是將其作為決策支援工具，並輔以人工監督、檢驗資料集、實施後監測、偏差評估、審計追蹤和清晰的升級規則。此外，人工智慧的實施凸顯了結構化資料、互通性標準和雲端基礎設施的重要性，因為無法在不同機構間可靠地傳輸影像資料會限制診斷速度。從長遠來看，人工智慧的累積效應預計將在以下方面最為顯著：降低診斷變異性、加快分流速度、提高灌注影像解讀的一致性以及更準確地分配患者，同時確保臨床課責和合規性。

區域性急性缺血性腦中風中風診斷的關鍵見解

在亞太地區，人口老化加劇、心臟代謝風險上升以及中風診療資源分配不均等問題，對急救醫療系統造成巨大壓力，導致急性缺血性腦中風診斷需求不斷增加。擁有先進影像基礎設施的國家正在加速推廣CT血管造影術、灌注成像、基於MRI的診療方案以及人工智慧輔助分診，而許多資源匱乏的地區則繼續優先發展基礎CT檢查、建設卒中單元、協調急救轉運以及遠端醫療。北美已建立一套成熟的中風體系，其核心是品質指標，例如認證中風中心、快速神經影像、遠端中風網路、急救服務路線規劃以及「入院至溶栓」時間。在改善都市區地區取栓分流的迫切需求下，該地區正在廣泛應用工作流程軟體、雲端影像共用以及人工智慧輔助的大血管閉塞檢測技術。在拉丁美洲，透過擴大中風中心網路、開展公共衛生舉措以及增加遠距醫療的使用，卒中防治工作正在取得進展，但及時影像檢查、獲得專科醫生診療以及轉診安排方面的差距仍然是重大障礙。在歐洲，結構化中風治療路徑、區域性取栓網路和既定臨床指南的實施已被證明行之有效，許多醫療系統都強調標準化影像檢查選擇、跨境研究合作以及公平地獲得再灌注治療。在中東，透過投資三級醫療機構、實現急救響應現代化以及培訓專科醫生，卒中診斷能力正在加強，這一趨勢在都市區尤為明顯，因為這些地區先進的CT和MRI設備正日益普及。非洲面臨最嚴峻的就醫挑戰，包括部分地區CT設備有限、就醫延遲、費用高昂以及神經科醫生和放射科醫生短缺。然而，有針對性地改善急救運輸系統、遠端醫療和基礎影像檢查能力可以顯著提高卒中診斷能力。

依戰略國家集團進行主要集團分析

東南亞國協正優先考慮透過加強急診醫療、改善CT掃描、建立轉診網路和遠端醫療方式切實擴大中風診斷範圍。雖然先進的影像設備主要集中在大都會醫院，但農村地區仍需要可擴展的分流和轉運模式。海灣合作理事會（GCC）國家的醫療衛生系統正在投資建設現代化醫院基礎設施、具備卒中診療能力的急診科、電子健康記錄和先進的神經影像技術，以支持三級醫療機構的快速診斷，並為製定區域統一的卒中診療方案創造機會。歐盟的特點是採用循證指南、制定國家級卒中預防計劃、建立高品質的登記系統和開展跨境合作，並強調公平地獲得具備取栓能力的醫療機構和統一的影像工作流程。金磚國家（BRICS）的診斷情況各不相同。中國和印度面臨沉重的卒中負擔，正在努力擴大影像檢查和卒中診療網路的覆蓋範圍。巴西儘管在醫療資源取得方面存在差異，但仍在製定區域性診療路徑。俄羅斯已在多個地區建立了血管中心模式，而南非仍在努力解決專家和基礎設施短缺的問題。七國集團（G7）國家在急性中風診斷方面普遍擁有高度發展的能力，CT掃描普及，急救醫療服務成熟，遠端醫療應用，特定診療路徑中可進行MRI檢查，並且擴大使用人工智慧影像分診技術。然而，農村地區的醫療資源和人員短缺仍然影響著診斷速度。北約成員國的中風診療體系與北美和高所得歐洲國家的卒中診療體系高度重合，在這些國家，互通性、網路安全、緊急應變能力和可靠的醫院影像基礎設施對於在日常診療和危機情況下維持可靠的急性中風診斷至關重要。

各國對急性缺血性腦中風診斷的重點見解

在美國，急性缺血性腦中風，擁有經認證的中風中心、急診醫療服務轉運路線、遠距中風醫療、先進的CT和MRI設備，以及人工智慧影像分診技術的快速應用。然而，區域性醫院的關閉和專科醫生的短缺仍然影響著及時診斷。加拿大受益於省級中風系統、高品質的影像標準和遠端保健諮詢，但區域性因素仍然給偏遠社區帶來挑戰。墨西哥正透過擴大醫院影像能力和專科醫生網路來加強卒中診療，但公立和私立醫療系統之間在醫療資源獲取方面的差異影響了診斷速度。巴西面臨沉重的卒中負擔，正在製定區域性卒中治療方案，但CT和血管造影術的及時應用以及轉運協調在不同地區差異顯著。在英國，一套嚴格遵循指南的系統性中風治療方案正在運行，取栓術的計畫已實現集中化，並且越來越重視救護車分診和人工智慧影像工作流程。德國擁有密集的醫院網路、先進的神經影像技術和完善的卒中單元，CT血管造影術和專家評估服務涵蓋範圍廣。法國支持組織完善的卒中網路、遠距遠端醫療（適用於偏遠地區的醫院）以及基於最新影像結果的治療方案選擇。俄羅斯已建立區域血管中心，以支持急性影像診斷和中風治療，但其廣大的地域導致醫療資源分配不均。義大利和西班牙在中風網路協調、取栓術和標準化影像方案方面持續改進，但區域差異影響著患者的診療路徑。中國正在擴大中風中心，拓展人工智慧輔助診斷和中風急救系統，以應對沉重的疾病負擔，但都市區醫療資源仍有差距。印度的卒中意識、CT普及率和三級卒中診療水平正在迅速提高，但就診延遲、經濟負擔和專家短缺仍然是重要的診斷障礙。日本擁有先進的影像基礎設施和積極的MRI應用，其人口老化使得快速中風診斷的需求居高不下。澳洲依靠協調一致的中風網路、遠端醫療和交通系統來覆蓋其廣闊的地域。同時，韓國透過結合先進的醫院影像技術、數位醫療的應用以及由專家主導的中風診療路徑，支持對急性缺血性腦中風進行快速評估。

為行業領導者提供的實用建議

行業領導者應將產品開發和服務策略與可衡量的臨床結果相結合，尤其要關注縮短影像檢查檢查時間、快速檢測主要血管閉塞、改進轉診決策以及持續識別符合取栓術條件的患者。診斷平台的設計應充分考慮與醫院資訊系統、放射科系統、影像存檔平台、急救醫療服務通訊以及行動中風團隊通知工具的互通性。供應商和醫療合作夥伴應優先考慮在不同掃描儀、影像方案、患者人群和醫療環境中檢驗，以確保性能可靠並減少演算法偏差。醫院和醫療系統應重點投資於標準化中風影像方案、全天候工作流程支援、員工培訓、遠距中風服務以及與治療時間表相關的品質改進儀錶板。在資源有限的環境中，擴大CT檢查的覆蓋範圍、加強轉診途徑、實施遠端專家診斷以及部署無需複雜基礎設施的經濟型工作流程工具是最可行的優先事項。政策制定者和保險公司不僅應支持技術的應用，還應支持重視加速實證診斷的報銷模式和採購標準。資料管治、網路安全、監管合規和上市後監管必須被視為核心要求，尤其對於人工智慧驅動的診斷解決方案而言更是如此。急診醫學、放射學、神經病學、神經外科、復健和公共衛生機構之間的策略合作對於建立一個能夠為都市區和醫療資源匱乏地區提供及時治療的、具有韌性的中風診斷夥伴關係至關重要。

調查方法

本執行摘要採用系統性的二手研究途徑編寫，以檢驗的臨床、監管和公共衛生資訊來源為中心。該調查方法包括對同行評審的卒中文獻、國際和國家臨床指南、醫院卒中治療方案標準、診斷血管攝影檢查監管文件、卒中負擔和危險因素的公共衛生數據以及人工智慧驅動的影像遠距中風醫療相關證據的審查。透過評估多個可靠資訊來源的一致性，優先考慮資料支持的臨床觀察而非宣傳性聲明，並排除無根據的假設，從而整合研究結果。分析考慮了診斷工作流程的績效、影像模式的使用、醫療保健系統的準備、區域准入障礙、人工智慧治理以及臨床應用因素。透過公開記錄的醫療保健基礎設施、卒中護理系統、影像設備可用性、急救轉運網路、專家資源以及數位醫療成熟度方面的差異，解讀區域、群體和國家層面的具體見解。本研究未採用任何市場管治、市佔率或預測假設。本研究方法強調證據的三角檢驗、與急性缺血性腦中風診斷的相關性以及對參與急診醫學、神經影像學、數位健康和​​中風護理系統開發的相關人員的實際適用性。

結論

隨著醫療系統認知到及時影像檢查和協作決策對於有效的再灌注治療至關重要，急性缺血性腦中風的診斷正變得更快、更協調，並日益依賴數據驅動。診斷流程正從孤立的影像解讀轉向整合中風工作流程，該流程結合了急診分診、高階神經影像、遠端中風會診、人工智慧預警和快速轉運協調。雖然在高所得地區，高階影像和數位化工作流程協調日趨完善，但許多新興市場和醫療資源匱乏的地區仍需要一些基礎投入，例如CT設備、訓練有素的人員、轉診系統和遠距專家支援。人工智慧（AI）有潛力幫助實現更快、更一致的診斷，尤其是在檢測主要血管閉塞和灌注評估方面，但其價值取決於檢驗、互通性、臨床監督和公平部署。專注於實證工作流程改善、監管可靠性和可擴展接觸模式的行業領導者將更有利於改善卒中治療效果。急性缺血性腦中風診斷的未來將取決於相關人員如何有效地將臨床標準、影像創新、數位連接和醫療保健系統改進結合起來，從而在正確的時間為每位患者提供正確的診斷。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章：急性缺血性腦中風診斷市場：依疾病類型分類

  • 栓塞
  • 湖相特性
  • 血栓性

第8章：急性缺血性腦中風的診斷市場：依診斷方式分類

  • 神經影像技術
    • 電腦斷層掃描（CT）
    • 磁振造影（MRI）
    • 正子斷層掃描（PET）
  • 基於超音波的技術
    • 頸動脈多普勒超音波檢查
    • 經顱都卜勒超音波
  • 臨床試驗
    • 血液生物標記檢測
    • 凝血功能檢測
  • 電診斷方法
  • 新型診斷技術

第9章：急性缺血性腦中風診斷市場：依最終用戶分類

  • 門診手術中心
  • 診斷中心
  • 醫院和診所
  • 研究所

第10章：急性缺血性腦中風診斷市場：依技術類型分類

  • 傳統醫學影像系統
  • 可攜式醫療影像系統
  • 即時診斷設備
  • 人工智慧驅動的診斷平台

第11章：急性缺血性腦中風診斷市場：按地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第12章：急性缺血性腦中風診斷市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第13章：急性缺血性腦中風診斷市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第14章 競爭格局

  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第15章：公司簡介

  • Abbott Laboratories
  • Aidoc Medical Ltd.
  • BIOTRONIK SE & Co KG
  • Boehringer Ingelheim International GmbH
  • Boston Scientific Corporation
  • Canon Medical Systems Corporation
  • F. Hoffmann-La Roche Ltd.
  • Fujifilm Holdings Corporation
  • GE Healthcare Technologies Inc.
  • Hitachi, Ltd.
  • Integral Diagnostics（IDX）Group
  • Johnson & Johnson Services, Inc.
  • Koninklijke Philips NV
  • Mediso Ltd.
  • Medtronic PLC
  • Merck & Co.
  • Neusoft Corporation
  • Nihon Kohden Corporation
  • Planmed Oy
  • Samsung Electronics Co. Ltd.
  • Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
  • Shimadzu Corporation
  • Shionogi & Co., Ltd.
  • Siemens Healthineers
  • Stryker Corporation
  • Toshiba International Corporation
Product Code: MRR-B16853776EA8

The Acute Ischemic Stroke Diagnosis Market is projected to grow by USD 6.47 billion at a CAGR of 7.13% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 3.99 billion
Estimated Year [2026] USD 4.24 billion
Forecast Year [2032] USD 6.47 billion
CAGR (%) 7.13%

Acute ischemic stroke diagnosis is a time-critical clinical pathway focused on rapidly identifying arterial occlusion, excluding hemorrhage, determining salvageable brain tissue, and guiding reperfusion decisions such as intravenous thrombolysis or endovascular thrombectomy. As ischemic stroke accounts for the majority of global stroke cases, diagnostic speed and accuracy directly influence disability, mortality, hospital length of stay, and long-term rehabilitation burden. Current workflows combine non-contrast computed tomography, CT angiography, CT perfusion, magnetic resonance imaging, laboratory assessment, stroke severity scoring, emergency medical services triage, and increasingly, artificial intelligence-enabled image interpretation. The clinical imperative is clear: every minute of untreated large vessel occlusion can result in substantial neuronal loss, making fast, standardized, and interoperable diagnostic systems essential across emergency departments, comprehensive stroke centers, and primary stroke centers. The acute ischemic stroke diagnosis landscape is being shaped by aging populations, rising prevalence of hypertension, diabetes, atrial fibrillation, obesity, and sedentary lifestyles, alongside greater awareness of transient ischemic attack and minor stroke evaluation. Health systems are prioritizing door-to-imaging, door-to-needle, and door-to-groin-puncture performance, while stroke networks are expanding telestroke, mobile stroke units, cloud-based imaging transfer, and hub-and-spoke consultation models. For industry stakeholders, the strongest opportunities are tied to evidence-based diagnostic acceleration, improved detection of large vessel occlusion and posterior circulation stroke, seamless workflow orchestration, and equitable access to advanced neuroimaging in underserved settings.

Transformative Shifts in the Acute Ischemic Stroke Diagnosis Landscape

The acute ischemic stroke diagnosis landscape is undergoing a structural shift from sequential, site-dependent assessment toward integrated, protocol-driven, and digitally connected care. Emergency stroke triage is moving upstream, with prehospital stroke scales, ambulance prenotification, and mobile imaging programs helping clinicians identify potential large vessel occlusion before hospital arrival. In-hospital pathways are also evolving as non-contrast CT remains the essential first-line tool for excluding intracranial hemorrhage, while CT angiography and CT perfusion are increasingly used to detect vessel occlusion, collateral status, infarct core, and penumbral tissue. Magnetic resonance imaging, including diffusion-weighted imaging, continues to support high-sensitivity detection in selected patients, especially when symptom onset is unclear or posterior fossa stroke is suspected. Another transformative shift is the widening treatment window for selected patients based on tissue-based imaging rather than time alone. Evidence-backed stroke protocols now emphasize individualized imaging criteria for thrombectomy eligibility, creating greater demand for rapid perfusion analysis, standardized interpretation, and multidisciplinary communication. Telestroke adoption is reducing geographic disparities by linking community hospitals with vascular neurologists and neurointerventional teams, while interoperable imaging platforms are enabling faster transfer decisions. At the same time, diagnostic quality is being influenced by regulatory expectations, cybersecurity requirements, data governance, and workforce shortages in radiology and neurology. The result is a market environment where clinical adoption depends not only on diagnostic accuracy, but also on workflow fit, real-world reliability, training requirements, reimbursement alignment, and measurable impact on treatment timelines.

Cumulative Impact of Artificial Intelligence on Stroke Diagnosis

Artificial intelligence is creating a cumulative impact across acute ischemic stroke diagnosis by supporting faster image review, automated detection of large vessel occlusion, infarct core estimation, perfusion mismatch assessment, hemorrhage exclusion support, and prioritization of urgent cases in radiology worklists. AI-enabled tools can reduce interpretation delays by alerting stroke teams when suspected occlusion or perfusion abnormality is detected, which is particularly valuable in hospitals with limited around-the-clock neuroradiology coverage. In practice, the greatest value is emerging when AI is integrated into the full stroke workflow: imaging acquisition, automated processing, mobile notification, multidisciplinary communication, treatment eligibility review, and transfer coordination. However, the impact of artificial intelligence is not uniform. Model performance can vary across scanner types, acquisition protocols, patient demographics, stroke mimics, posterior circulation occlusions, small infarcts, and motion-degraded imaging. For this reason, clinical governance is essential. High-performing stroke programs are treating AI as decision support rather than autonomous diagnosis, using human oversight, validation datasets, post-deployment monitoring, bias assessment, audit trails, and clear escalation rules. AI is also increasing the importance of structured data, interoperability standards, and cloud-enabled infrastructure, because diagnostic speed is limited when imaging cannot move reliably between facilities. Over time, the cumulative effect of AI is expected to be strongest in reducing variability, supporting faster triage, improving consistency of perfusion interpretation, and enabling more precise patient routing, while maintaining clinical accountability and regulatory compliance.

Key Regional Insights Across Acute Ischemic Stroke Diagnosis

Asia-Pacific is experiencing rising demand for acute ischemic stroke diagnosis as large aging populations, increasing cardiometabolic risk, and unequal access to stroke-ready hospitals place pressure on emergency care systems. Countries with advanced imaging infrastructure are accelerating adoption of CT angiography, perfusion imaging, MRI-based protocols, and AI-assisted triage, while many lower-resource areas continue to prioritize broader access to basic CT, stroke unit development, emergency transport coordination, and telemedicine. North America demonstrates mature stroke systems built around certified stroke centers, rapid neuroimaging, telestroke networks, emergency medical services routing, and quality metrics such as door-to-needle performance. The region shows strong uptake of workflow software, cloud-based image sharing, and AI-supported large vessel occlusion detection, driven by the need to improve thrombectomy triage across urban and rural settings. Latin America is advancing through expanding stroke center networks, public health initiatives, and greater use of teleconsultation, although disparities in timely imaging, specialist access, and transfer logistics remain major barriers. Europe benefits from organized stroke pathways, regional thrombectomy networks, and established clinical guideline adoption, with many health systems emphasizing standardized imaging selection, cross-border research collaboration, and equitable access to reperfusion therapy. The Middle East is strengthening stroke diagnosis through investment in tertiary hospitals, emergency response modernization, and specialist workforce development, particularly in urban centers where advanced CT and MRI capabilities are increasingly available. Africa faces the most pronounced access challenges, including limited CT availability in some areas, delayed presentation, cost barriers, and shortages of neurologists and radiologists; however, targeted improvements in emergency referral systems, telemedicine, and basic imaging capacity can deliver substantial diagnostic gains.

Key Group Insights Across Strategic Country Blocs

ASEAN countries are prioritizing practical expansion of stroke diagnosis through emergency care strengthening, CT accessibility, referral networks, and telemedicine, with advanced imaging concentrated in major metropolitan hospitals while rural settings require scalable triage and transfer models. GCC health systems are investing in modern hospital infrastructure, stroke-ready emergency departments, digital health records, and advanced neuroimaging, supporting faster diagnosis in tertiary centers and creating opportunities for standardized regional stroke protocols. The European Union is characterized by evidence-led guideline adoption, national stroke plans, quality registries, and cross-country collaboration, with a strong emphasis on equitable access to thrombectomy-capable centers and harmonized imaging workflows. BRICS countries present a diverse diagnostic landscape: China and India face large stroke burdens and are expanding imaging access and stroke networks, Brazil is developing regionalized care pathways despite access disparities, Russia has established vascular center models in many areas, and South Africa continues to address specialist and infrastructure gaps. G7 nations generally have advanced acute stroke diagnosis capabilities, including widespread CT access, mature emergency medical services, telemedicine coverage, MRI availability in selected pathways, and growing use of AI-assisted imaging triage, although rural access and workforce shortages still affect timeliness. NATO countries overlap substantially with high-income stroke systems in North America and Europe, where interoperability, cybersecurity, emergency preparedness, and resilient hospital imaging infrastructure are increasingly important for sustaining reliable acute stroke diagnosis during routine care and crisis conditions.

Key Country Insights in Acute Ischemic Stroke Diagnosis

The United States has a highly developed acute ischemic stroke diagnosis ecosystem supported by stroke center certification, emergency medical services routing, telestroke, advanced CT and MRI access, and rapid adoption of AI-assisted image triage, though rural hospital closures and specialist shortages continue to affect timely diagnosis. Canada benefits from organized provincial stroke systems, high-quality imaging standards, and telehealth-enabled consultation, with geography creating persistent challenges for remote communities. Mexico is strengthening stroke care through expanding hospital imaging capability and specialist networks, while uneven access between public and private systems influences diagnostic speed. Brazil faces a high stroke burden and is advancing regional stroke pathways, but timely CT, vascular imaging, and transfer coordination vary significantly across regions. The United Kingdom operates structured stroke pathways with strong guideline alignment, centralized thrombectomy planning, and growing focus on ambulance triage and AI-supported imaging workflows. Germany has a dense hospital network, advanced neuroimaging, and established stroke units, enabling broad access to CT angiography and specialist assessment. France supports organized stroke networks, telemedicine for remote hospitals, and modern imaging-based treatment selection. Russia has developed regional vascular centers that support acute imaging and stroke treatment, although access varies across vast geographic areas. Italy and Spain continue to improve stroke network coordination, thrombectomy access, and standardized imaging protocols, with regional variability shaping patient pathways. China is expanding stroke center capacity, AI-enabled diagnostics, and emergency stroke systems in response to a large disease burden, while differences remain between urban and rural facilities. India is rapidly improving awareness, CT availability, and tertiary stroke care, but delayed presentation, affordability, and limited specialist coverage remain important diagnostic barriers. Japan has advanced imaging infrastructure, strong MRI utilization, and an aging population that sustains high demand for rapid stroke diagnosis. Australia relies on coordinated stroke networks, telehealth, and retrieval systems to support large geographic coverage, while South Korea combines advanced hospital imaging, digital health adoption, and specialist-led stroke pathways to support rapid acute ischemic stroke evaluation.

Actionable Recommendations for Industry Leaders

Industry leaders should align product development and service strategies with measurable clinical outcomes, especially reduced door-to-imaging time, faster large vessel occlusion detection, improved transfer decisions, and consistent identification of thrombectomy-eligible patients. Diagnostic platforms should be designed for interoperability with hospital information systems, radiology systems, picture archiving platforms, emergency medical services communication, and mobile stroke team notification tools. Vendors and healthcare partners should prioritize validation across diverse scanners, imaging protocols, demographics, and care settings to ensure reliable performance and reduce algorithmic bias. For hospitals and health systems, investment should focus on standardized stroke imaging protocols, 24/7 workflow readiness, staff training, telestroke coverage, and quality improvement dashboards tied to treatment timelines. In lower-resource settings, the most actionable priorities are expanding CT access, strengthening referral pathways, enabling remote specialist review, and deploying affordable workflow tools that do not require complex infrastructure. Policymakers and payers should support reimbursement models and procurement criteria that reward evidence-based diagnostic acceleration, not technology adoption alone. Data governance, cybersecurity, regulatory compliance, and post-market monitoring must be treated as core requirements, particularly for AI-enabled diagnostic solutions. Strategic partnerships across emergency medicine, radiology, neurology, neurosurgery, rehabilitation, and public health agencies will be essential to build resilient stroke diagnosis systems that deliver timely care across both urban and underserved populations.

Research Methodology

This executive summary is developed using a structured secondary research approach centered on verified clinical, regulatory, and public health sources. The methodology includes review of peer-reviewed stroke literature, international and national clinical guidelines, hospital stroke pathway standards, regulatory documentation for diagnostic technologies, public health data on stroke burden and risk factors, and evidence related to CT, CT angiography, CT perfusion, MRI, telestroke, and AI-supported imaging workflows. Insights are synthesized by evaluating consistency across multiple credible sources, prioritizing data-backed clinical findings over promotional claims, and excluding unsupported assumptions. The analysis considers diagnostic workflow performance, imaging modality utilization, health system readiness, regional access barriers, artificial intelligence governance, and clinical adoption factors. Regional, group, and country insights are interpreted through publicly documented differences in healthcare infrastructure, stroke systems of care, imaging availability, emergency transport networks, specialist capacity, and digital health maturity. No market sizing, market share, or forecasting assumptions are applied. The research approach emphasizes evidence triangulation, relevance to acute ischemic stroke diagnosis, and practical applicability for stakeholders involved in emergency care, neuroimaging, digital health, and stroke system development.

Conclusion

Acute ischemic stroke diagnosis is becoming faster, more connected, and increasingly data-driven as health systems recognize that timely imaging and coordinated decision-making are central to effective reperfusion care. The diagnostic pathway is shifting from isolated image interpretation toward integrated stroke workflows that combine emergency triage, advanced neuroimaging, telestroke consultation, AI-enabled alerts, and rapid transfer coordination. While high-income regions are refining advanced imaging and digital workflow orchestration, many emerging and underserved markets still require foundational investments in CT access, trained personnel, referral systems, and remote specialist support. Artificial intelligence has the potential to improve speed and consistency, particularly for large vessel occlusion detection and perfusion interpretation, but its value depends on validation, interoperability, clinical oversight, and equitable deployment. Industry leaders that focus on evidence-based workflow improvement, regulatory-grade reliability, and scalable access models will be best positioned to support better stroke outcomes. The future of acute ischemic stroke diagnosis will be defined by how effectively stakeholders combine clinical standards, imaging innovation, digital connectivity, and health system readiness to deliver the right diagnosis at the right time for every patient.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. New Revenue Opportunities
  • 3.5. Next-Generation Business Models
  • 3.6. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Acute Ischemic Stroke Diagnosis Market, by Disease Type

  • 7.1. Introduction
  • 7.2. Embolic
  • 7.3. Lacunar
  • 7.4. Thrombotic

8. Acute Ischemic Stroke Diagnosis Market, by Diagnostic Modality

  • 8.1. Introduction
  • 8.2. Neuroimaging Techniques
    • 8.2.1. Computed Tomography (CT)
    • 8.2.2. Magnetic Resonance Imaging (MRI)
    • 8.2.3. Positron Emission Tomography (PET)
  • 8.3. Ultrasound Based Techniques
    • 8.3.1. Carotid Doppler Ultrasound
    • 8.3.2. Transcranial Doppler Ultrasound
  • 8.4. Laboratory Diagnostics
    • 8.4.1. Blood Biomarker Testing
    • 8.4.2. Coagulation Profile Testing
  • 8.5. Electrodiagnostic Techniques
  • 8.6. Emerging Diagnostic Techniques

9. Acute Ischemic Stroke Diagnosis Market, by End-User

  • 9.1. Introduction
  • 9.2. Ambulatory Surgical Centers
  • 9.3. Diagnostic Centers
  • 9.4. Hospitals & Clinics
  • 9.5. Research Laboratories

10. Acute Ischemic Stroke Diagnosis Market, by Technology Type

  • 10.1. Introduction
  • 10.2. Conventional Imaging Systems
  • 10.3. Portable Imaging Systems
  • 10.4. Point Of Care Diagnostic Devices
  • 10.5. AI Assisted Diagnostic Platforms

11. Acute Ischemic Stroke Diagnosis Market, by Region

  • 11.1. Asia-Pacific
  • 11.2. North America
  • 11.3. Latin America
  • 11.4. Europe
  • 11.5. Middle East
  • 11.6. Africa

12. Acute Ischemic Stroke Diagnosis Market, by Group

  • 12.1. ASEAN
  • 12.2. GCC
  • 12.3. European Union
  • 12.4. BRICS
  • 12.5. G7
  • 12.6. NATO

13. Acute Ischemic Stroke Diagnosis Market, by Country

  • 13.1. United States
  • 13.2. Canada
  • 13.3. Mexico
  • 13.4. Brazil
  • 13.5. United Kingdom
  • 13.6. Germany
  • 13.7. France
  • 13.8. Russia
  • 13.9. Italy
  • 13.10. Spain
  • 13.11. China
  • 13.12. India
  • 13.13. Japan
  • 13.14. Australia
  • 13.15. South Korea

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2025
  • 14.2. FPNV Positioning Matrix, 2025
  • 14.3. Market Concentration Analysis, 2025
    • 14.3.1. Concentration Ratio (CR)
    • 14.3.2. Herfindahl Hirschman Index (HHI)
  • 14.4. Recent Developments & Impact Analysis, 2025
  • 14.5. Product Portfolio Analysis, 2025
  • 14.6. Benchmarking Analysis, 2025

15. Company Profiles

  • 15.1. Abbott Laboratories
  • 15.2. Aidoc Medical Ltd.
  • 15.3. BIOTRONIK SE & Co KG
  • 15.4. Boehringer Ingelheim International GmbH
  • 15.5. Boston Scientific Corporation
  • 15.6. Canon Medical Systems Corporation
  • 15.7. F. Hoffmann-La Roche Ltd.
  • 15.8. Fujifilm Holdings Corporation
  • 15.9. GE Healthcare Technologies Inc.
  • 15.10. Hitachi, Ltd.
  • 15.11. Integral Diagnostics (IDX) Group
  • 15.12. Johnson & Johnson Services, Inc.
  • 15.13. Koninklijke Philips N.V.
  • 15.14. Mediso Ltd.
  • 15.15. Medtronic PLC
  • 15.16. Merck & Co.
  • 15.17. Neusoft Corporation
  • 15.18. Nihon Kohden Corporation
  • 15.19. Planmed Oy
  • 15.20. Samsung Electronics Co. Ltd.
  • 15.21. Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
  • 15.22. Shimadzu Corporation
  • 15.23. Shionogi & Co., Ltd.
  • 15.24. Siemens Healthineers
  • 15.25. Stryker Corporation
  • 15.26. Toshiba International Corporation

LIST OF FIGURES

  • FIGURE 1. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2025 VS 2032 (%)
  • FIGURE 7. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC MODALITY, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC MODALITY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY END-USER, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY END-USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TECHNOLOGY TYPE, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TECHNOLOGY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 21. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

LIST OF TABLES

  • TABLE 1. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL EMBOLIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL EMBOLIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL EMBOLIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL LACUNAR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL LACUNAR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL LACUNAR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL THROMBOTIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL THROMBOTIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL THROMBOTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC MODALITY, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL NEUROIMAGING TECHNIQUES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL NEUROIMAGING TECHNIQUES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL NEUROIMAGING TECHNIQUES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL COMPUTED TOMOGRAPHY (CT) MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL COMPUTED TOMOGRAPHY (CT) MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL COMPUTED TOMOGRAPHY (CT) MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL MAGNETIC RESONANCE IMAGING (MRI) MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL MAGNETIC RESONANCE IMAGING (MRI) MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL MAGNETIC RESONANCE IMAGING (MRI) MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL POSITRON EMISSION TOMOGRAPHY (PET) MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL POSITRON EMISSION TOMOGRAPHY (PET) MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL POSITRON EMISSION TOMOGRAPHY (PET) MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ULTRASOUND BASED TECHNIQUES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ULTRASOUND BASED TECHNIQUES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ULTRASOUND BASED TECHNIQUES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CAROTID DOPPLER ULTRASOUND MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CAROTID DOPPLER ULTRASOUND MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CAROTID DOPPLER ULTRASOUND MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL TRANSCRANIAL DOPPLER ULTRASOUND MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL TRANSCRANIAL DOPPLER ULTRASOUND MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL TRANSCRANIAL DOPPLER ULTRASOUND MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL LABORATORY DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL LABORATORY DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL LABORATORY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL BLOOD BIOMARKER TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL BLOOD BIOMARKER TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL BLOOD BIOMARKER TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL COAGULATION PROFILE TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL COAGULATION PROFILE TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL COAGULATION PROFILE TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ELECTRODIAGNOSTIC TECHNIQUES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ELECTRODIAGNOSTIC TECHNIQUES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ELECTRODIAGNOSTIC TECHNIQUES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL EMERGING DIAGNOSTIC TECHNIQUES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL EMERGING DIAGNOSTIC TECHNIQUES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL EMERGING DIAGNOSTIC TECHNIQUES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL DIAGNOSTIC CENTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL DIAGNOSTIC CENTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL DIAGNOSTIC CENTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL RESEARCH LABORATORIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL RESEARCH LABORATORIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL RESEARCH LABORATORIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL CONVENTIONAL IMAGING SYSTEMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL CONVENTIONAL IMAGING SYSTEMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL CONVENTIONAL IMAGING SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL PORTABLE IMAGING SYSTEMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL PORTABLE IMAGING SYSTEMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL PORTABLE IMAGING SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL POINT OF CARE DIAGNOSTIC DEVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL POINT OF CARE DIAGNOSTIC DEVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL POINT OF CARE DIAGNOSTIC DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL AI ASSISTED DIAGNOSTIC PLATFORMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL AI ASSISTED DIAGNOSTIC PLATFORMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL AI ASSISTED DIAGNOSTIC PLATFORMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. ASIA-PACIFIC ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. ASIA-PACIFIC ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 79. ASIA-PACIFIC ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC MODALITY, 2018-2032 (USD MILLION)
  • TABLE 80. ASIA-PACIFIC ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY NEUROIMAGING TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 81. ASIA-PACIFIC ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY ULTRASOUND BASED TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 82. ASIA-PACIFIC ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY LABORATORY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 83. ASIA-PACIFIC ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 84. ASIA-PACIFIC ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. NORTH AMERICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 87. NORTH AMERICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC MODALITY, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY NEUROIMAGING TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 89. NORTH AMERICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY ULTRASOUND BASED TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 90. NORTH AMERICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY LABORATORY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 92. NORTH AMERICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 93. LATIN AMERICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. LATIN AMERICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 95. LATIN AMERICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC MODALITY, 2018-2032 (USD MILLION)
  • TABLE 96. LATIN AMERICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY NEUROIMAGING TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 97. LATIN AMERICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY ULTRASOUND BASED TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 98. LATIN AMERICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY LABORATORY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 99. LATIN AMERICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 100. LATIN AMERICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC MODALITY, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY NEUROIMAGING TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY ULTRASOUND BASED TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY LABORATORY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. MIDDLE EAST ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 110. MIDDLE EAST ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 111. MIDDLE EAST ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC MODALITY, 2018-2032 (USD MILLION)
  • TABLE 112. MIDDLE EAST ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY NEUROIMAGING TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 113. MIDDLE EAST ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY ULTRASOUND BASED TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 114. MIDDLE EAST ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY LABORATORY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 115. MIDDLE EAST ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 116. MIDDLE EAST ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 117. AFRICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 118. AFRICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. AFRICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC MODALITY, 2018-2032 (USD MILLION)
  • TABLE 120. AFRICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY NEUROIMAGING TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 121. AFRICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY ULTRASOUND BASED TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 122. AFRICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY LABORATORY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 123. AFRICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 124. AFRICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 126. ASEAN ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 127. ASEAN ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. ASEAN ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC MODALITY, 2018-2032 (USD MILLION)
  • TABLE 129. ASEAN ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY NEUROIMAGING TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 130. ASEAN ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY ULTRASOUND BASED TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 131. ASEAN ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY LABORATORY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 132. ASEAN ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 133. ASEAN ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. GCC ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 135. GCC ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. GCC ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC MODALITY, 2018-2032 (USD MILLION)
  • TABLE 137. GCC ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY NEUROIMAGING TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 138. GCC ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY ULTRASOUND BASED TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 139. GCC ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY LABORATORY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 140. GCC ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 141. GCC ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPEAN UNION ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPEAN UNION ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPEAN UNION ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC MODALITY, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPEAN UNION ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY NEUROIMAGING TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPEAN UNION ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY ULTRASOUND BASED TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPEAN UNION ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY LABORATORY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPEAN UNION ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPEAN UNION ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 150. BRICS ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 151. BRICS ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 152. BRICS ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC MODALITY, 2018-2032 (USD MILLION)
  • TABLE 153. BRICS ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY NEUROIMAGING TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 154. BRICS ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY ULTRASOUND BASED TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 155. BRICS ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY LABORATORY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 156. BRICS ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 157. BRICS ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. G7 ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 159. G7 ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. G7 ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC MODALITY, 2018-2032 (USD MILLION)
  • TABLE 161. G7 ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY NEUROIMAGING TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 162. G7 ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY ULTRASOUND BASED TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 163. G7 ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY LABORATORY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 164. G7 ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 165. G7 ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. NATO ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 167. NATO ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 168. NATO ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC MODALITY, 2018-2032 (USD MILLION)
  • TABLE 169. NATO ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY NEUROIMAGING TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 170. NATO ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY ULTRASOUND BASED TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 171. NATO ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY LABORATORY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 172. NATO ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 173. NATO ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 174. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. UNITED STATES ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 176. UNITED STATES ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 177. UNITED STATES ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC MODALITY, 2018-2032 (USD MILLION)
  • TABLE 178. UNITED STATES ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY NEUROIMAGING TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 179. UNITED STATES ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY ULTRASOUND BASED TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 180. UNITED STATES ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY LABORATORY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 181. UNITED STATES ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 182. UNITED STATES ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 183. CANADA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 184. CANADA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. CANADA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC MODALITY, 2018-2032 (USD MILLION)
  • TABLE 186. CANADA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY NEUROIMAGING TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 187. CANADA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY ULTRASOUND BASED TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 188. CANADA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY LABORATORY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 189. CANADA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 190. CANADA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. MEXICO ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 192. MEXICO ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 193. MEXICO ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC MODALITY, 2018-2032 (USD MILLION)
  • TABLE 194. MEXICO ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY NEUROIMAGING TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 195. MEXICO ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY ULTRASOUND BASED TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 196. MEXICO ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY LABORATORY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 197. MEXICO ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 198. MEXICO ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 199. BRAZIL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 200. BRAZIL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 201. BRAZIL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC MODALITY, 2018-2032 (USD MILLION)
  • TABLE 202. BRAZIL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY NEUROIMAGING TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 203. BRAZIL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY ULTRASOUND BASED TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 204. BRAZIL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY LABORATORY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 205. BRAZIL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 206. BRAZIL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 207. UNITED KINGDOM ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 208. UNITED KINGDOM ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 209. UNITED KINGDOM ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC MODALITY, 2018-2032 (USD MILLION)
  • TABLE 210. UNITED KINGDOM ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY NEUROIMAGING TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 211. UNITED KINGDOM ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY ULTRASOUND BASED TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 212. UNITED KINGDOM ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY LABORATORY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 213. UNITED KINGDOM ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 214. UNITED KINGDOM ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 215. GERMANY ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 216. GERMANY ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 217. GERMANY ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC MODALITY, 2018-2032 (USD MILLION)
  • TABLE 218. GERMANY ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY NEUROIMAGING TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 219. GERMANY ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY ULTRASOUND BASED TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 220. GERMANY ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY LABORATORY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 221. GERMANY ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 222. GERMANY ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 223. FRANCE ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 224. FRANCE ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 225. FRANCE ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC MODALITY, 2018-2032 (USD MILLION)
  • TABLE 226. FRANCE ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY NEUROIMAGING TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 227. FRANCE ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY ULTRASOUND BASED TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 228. FRANCE ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY LABORATORY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 229. FRANCE ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 230. FRANCE ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 231. RUSSIA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 232. RUSSIA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 233. RUSSIA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC MODALITY, 2018-2032 (USD MILLION)
  • TABLE 234. RUSSIA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY NEUROIMAGING TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 235. RUSSIA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY ULTRASOUND BASED TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 236. RUSSIA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY LABORATORY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 237. RUSSIA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 238. RUSSIA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 239. ITALY ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 240. ITALY ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 241. ITALY ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC MODALITY, 2018-2032 (USD MILLION)
  • TABLE 242. ITALY ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY NEUROIMAGING TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 243. ITALY ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY ULTRASOUND BASED TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 244. ITALY ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY LABORATORY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 245. ITALY ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 246. ITALY ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 247. SPAIN ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 248. SPAIN ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 249. SPAIN ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC MODALITY, 2018-2032 (USD MILLION)
  • TABLE 250. SPAIN ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY NEUROIMAGING TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 251. SPAIN ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY ULTRASOUND BASED TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 252. SPAIN ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY LABORATORY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 253. SPAIN ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 254. SPAIN ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 255. CHINA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 256. CHINA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 257. CHINA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC MODALITY, 2018-2032 (USD MILLION)
  • TABLE 258. CHINA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY NEUROIMAGING TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 259. CHINA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY ULTRASOUND BASED TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 260. CHINA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY LABORATORY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 261. CHINA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 262. CHINA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 263. INDIA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 264. INDIA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 265. INDIA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC MODALITY, 2018-2032 (USD MILLION)
  • TABLE 266. INDIA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY NEUROIMAGING TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 267. INDIA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY ULTRASOUND BASED TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 268. INDIA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY LABORATORY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 269. INDIA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 270. INDIA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 271. JAPAN ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 272. JAPAN ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 273. JAPAN ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC MODALITY, 2018-2032 (USD MILLION)
  • TABLE 274. JAPAN ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY NEUROIMAGING TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 275. JAPAN ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY ULTRASOUND BASED TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 276. JAPAN ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY LABORATORY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 277. JAPAN ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 278. JAPAN ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 279. AUSTRALIA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 280. AUSTRALIA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 281. AUSTRALIA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC MODALITY, 2018-2032 (USD MILLION)
  • TABLE 282. AUSTRALIA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY NEUROIMAGING TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 283. AUSTRALIA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY ULTRASOUND BASED TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 284. AUSTRALIA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY LABORATORY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 285. AUSTRALIA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 286. AUSTRALIA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 287. SOUTH KOREA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 288. SOUTH KOREA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 289. SOUTH KOREA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC MODALITY, 2018-2032 (USD MILLION)
  • TABLE 290. SOUTH KOREA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY NEUROIMAGING TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 291. SOUTH KOREA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY ULTRASOUND BASED TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 292. SOUTH KOREA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY LABORATORY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 293. SOUTH KOREA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 294. SOUTH KOREA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 295. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SHARE, BY KEY PLAYER, 2025
  • TABLE 296. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025